Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| MedTech Acquisition Corporation | MTACU | NASDAQ | Trust |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 11.35 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 11.35 |
| Trades | Volume | Avg Volume |
|---|---|---|
| 0 | 0 | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | 11.35 | USD |
MedTech Acquisition Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 22.17M | 1.95M | - | 18.51M | -63.28M | -32.40 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News MedTech Acquisition
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
MTACU Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| TriSalus Life Sciences was created to develop and commercialize an innovative approach for the treatment of liver and pancreatic tumors. Our platform approach addresses immune dysfunction in liver and pancreatic tumors by combining immunotherapy drugs with highly effective drug delivery technology. Our companyâ¿¿s heritage is in the development of devices for our Pressure-Enabled Drug Deliveryâ¿¢ (PEDDâ¿¢) method. Building on this history, we launched our new platform in 2020 with the acquisition of SD-101. SD-101 is an investigational toll-like receptor 9 (TLR9) agonist with the potential to modulate the immune system to enable immunotherapy. |
MTACU -
What is the current MedTech Acquisition Corporation share price?
The current share price of MedTech Acquisition Corporation is $ 11.35
How many MedTech Acquisition Corporation shares are in issue?
MedTech Acquisition Corporation has 1,953,000 shares in issue
What is the market cap of MedTech Acquisition Corporation?
The market capitalisation of MedTech Acquisition Corporation is USD 22.17M
What is the 1 year trading range for MedTech Acquisition Corporation share price?
MedTech Acquisition Corporation has traded in the range of $ 0.00 to $ 0.00 during the past year
What is the PE ratio of MedTech Acquisition Corporation?
The price to earnings ratio of MedTech Acquisition Corporation is -0.35
What is the cash to sales ratio of MedTech Acquisition Corporation?
The cash to sales ratio of MedTech Acquisition Corporation is 1.2
What is the reporting currency for MedTech Acquisition Corporation?
MedTech Acquisition Corporation reports financial results in USD
What is the latest annual turnover for MedTech Acquisition Corporation?
The latest annual turnover of MedTech Acquisition Corporation is USD 18.51M
What is the latest annual profit for MedTech Acquisition Corporation?
The latest annual profit of MedTech Acquisition Corporation is USD -63.28M
What is the registered address of MedTech Acquisition Corporation?
The registered address for MedTech Acquisition Corporation is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
Which industry sector does MedTech Acquisition Corporation operate in?
MedTech Acquisition Corporation operates in the BLANK CHECKS sector
